Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

YSPSL

Next Previous
X
Search
Drug Profile

YSPSL

Alternative Names: PSGL-1Ig; Recombinant P-selectin glycoprotein ligand-1 fusion protein; rPSGL-Ig

Latest Information Update: 11 Sep 2015

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Wyeth
  • Developer Wyeth; Ys Therapeutics
  • Class Anti-inflammatories; Anti-ischaemics; Antithrombotics; Recombinant fusion proteins
  • Mechanism of Action P-selectin ligand protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Delayed graft function
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Deep vein thrombosis; Delayed graft function; Inflammation; Myocardial infarction; Ocular inflammation; Renal transplant rejection; Reperfusion injury; Sickle cell anaemia; Thrombosis

Most Recent Events

  • 11 Sep 2015 Discontinued - Phase-I/II for Delayed graft function (Prevention) in USA (IV)
  • 11 Sep 2015 Discontinued - Phase-II for Reperfusion injury (Prevention) in USA (IV)
  • 11 Sep 2015 Discontinued for Inflammation in USA (unspecified route)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top